Carfilzomib, Lenalidomide, And Dexamethasone (Krd) Versus Bortezomib, Lenalidomide, And Dexamethasone (Vrd) For Initial Therapy Of Newly Diagnosed Multiple Myeloma (Ndmm): Results Of Endurance (E1a11) Phase Iii Trial

Shaji Kumar,Susanna J. Jacobus,Adam D. Cohen,Matthias Weiss,Natalie Scott Callander, Avina A. Singh,Terri L. Parker,Alex R. Menter,Xuezhong Yang,Benjamin Marshall Parsons,Pankaj Kumar,Prashant Kapoor,Aaron Seth Rosenberg,Jeffrey A. Zonder, Edward Anthony Faber,Sagar Lonial,Paul G. Richardson,Robert Z. Orlowski,Lynne I. Wagner,S. Vincent Rajkumar

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 44|浏览30

暂无评分

摘要

LBA3Background: Bortezomib (btz) combined with lenalidomide (len) and dexamethasone (dex) (VRd) is a standard initial therapy for NDMM. Carfilzomib (cfz), a next-generation proteasome inhibitor, in...

查看译文

关键词

283-224-288-3564261-492-27693223553611458764

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要